Checkpoint Therapeutics Inc (NASDAQ:CKPT) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price objective of $15.50 for the company and are forecasting that the company will post ($0.35) EPS for the current quarter, according to Zacks. Zacks has also given Checkpoint Therapeutics an industry rank of 160 out of 255 based on the ratings given to related companies.
CKPT has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research report on Thursday, March 29th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Checkpoint Therapeutics in a research report on Friday, May 11th. Finally, ValuEngine upgraded shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
A hedge fund recently bought a new stake in Checkpoint Therapeutics stock. Millennium Management LLC bought a new stake in shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) during the 1st quarter, according to its most recent filing with the SEC. The fund bought 75,390 shares of the company’s stock, valued at approximately $331,000. Millennium Management LLC owned approximately 0.24% of Checkpoint Therapeutics as of its most recent filing with the SEC. Institutional investors own 1.47% of the company’s stock.
Checkpoint Therapeutics opened at $2.76 on Wednesday, according to Marketbeat Ratings. The firm has a market capitalization of $90.92 million and a price-to-earnings ratio of -2.76. Checkpoint Therapeutics has a 52-week low of $2.25 and a 52-week high of $10.50.
Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Thursday, May 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.13). Checkpoint Therapeutics had a negative return on equity of 122.20% and a negative net margin of 1,967.93%. The company had revenue of $0.34 million during the quarter. sell-side analysts predict that Checkpoint Therapeutics will post -1.36 earnings per share for the current fiscal year.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.